Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Trial of TMS Therapy for Bipolar Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria- Phase II:~1. Must be at least 18 years old.~2. Must meet DSM-5 criteria for bipolar (either I or II) depression by clinical interview and M.I.N.I. The duration of the current depressive episode must be at least 4 weeks and no longer than 3 years in length.~3. Should have a MADRS score of at least 20 at screening, an YMRS score of less than 12 and a CGI score of at least 4.~4. Must have signed the informed consent document and have a level of understanding sufficient to provide informed consent and to communicate with the investigator and site personnel.~5. Must be on a mood stabilizer acceptable to the study physician which is consistent with their diagnosis. The mood stabilizer must be at a stable dose for at least four days before starting TMS treatment.~6. If female of childbearing potential, patients must~   1. have a negative urine pregnancy test at screening, and~  2. not be nursing or planning a pregnancy, and~  3. be on a medically acceptable method of birth control acceptable to the principal investigator.~Choices of contraception that meet the study requirements are~* Intrauterine device~* Hormonal contraception (estrogen-containing birth control pills, Vaginal ring, patch, injections or implants)~* Latex condom with spermicide~* Diaphragm with spermicide~* Cervical cap with spermicide~Females of childbearing potential who are abstinent can enroll in the study.~Exclusion Criteria- Phase II:~1. May not be directly affiliated with Sheppard Pratt Clinical Research Programs or be immediate family of Research Programs personnel.~2. Must not have another primary Axis I diagnosis.~3. The subject must not have stopped an antidepressant less than two weeks before starting TMS treatment or unable to discontinue antidepressant therapy.~4. Should have no previous history of psychosis or substance dependence or abuse within the six months prior to Screening~5. Presence of an Axis II disorder felt by the investigator to potentially interfere with study compliance would exclude a potential participant.~6. Should not have prior intolerance of TMS or significant lack of response to adequate trials of TMS.~7. Should not have a lifetime history of lack of response to ECT or VNS.~8. Should not have any medical condition likely to interfere with safe study participation.~9. Women of child-bearing potential who are not using a medically accepted means of contraception when engaging in sexual intercourse are excluded, as well as women who are pregnant or breast-feeding.~10. Positive urine screen for any substance of abuse will exclude a patient, with the exception of benzodiazepines. A satisfactory explanation in the opinion of the investigator along with a negative repeat screen prior to Visit 2 is possibly acceptable.~11. Current suicide risk, as evidenced:~    1. It is the judgment of the investigator that the patient may be at risk for suicide~   2. The patient has rated a yes to question 4 or question 5 on the Screening C-SSRS~   3. The patient has attempted suicide within the past 12 months prior to Screening.~12. History of head injury, epilepsy or seizure disorder, non-removable metallic implants or objects in or around the head.~Inclusion Criteria- Phase III Patients who meet MADRS criteria for response or remission will enter Phase III, the six month follow-up phase of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-Label TMS (Type: EXPERIMENTAL): Active Transcranial Magnetic Stimulation

Based on this trial design, predict the completion outcome and termination type (if applicable).